These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6712828)

  • 1. Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.
    Cosi V; Romani A; Callieco R; Zerbi F
    Boll Soc Ital Biol Sper; 1984 Mar; 60(3):603-9. PubMed ID: 6712828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism.
    Sollazzo D
    Electroencephalogr Clin Neurophysiol; 1985 Oct; 61(4):236-42. PubMed ID: 2411501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromatic and achromatic visual evoked potentials in Parkinson's disease.
    Büttner T; Kuhn W; Müller T; Heinze T; Pühl C; Przuntek H
    Electroencephalogr Clin Neurophysiol; 1996 Sep; 100(5):443-7. PubMed ID: 8893662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic deficiency and delayed visual evoked potentials in humans.
    Bodis-Wollner I; Yahr MD; Mylin L; Thornton J
    Ann Neurol; 1982 May; 11(5):478-83. PubMed ID: 6125124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auditory evoked potentials (AEPs), early (BAEPs) and long latency components (LLCs) in Parkinson's disease: a 12 month follow-up study.
    Bindi A; Russo G; Benvenuti F; Bandinelli S; Ferrucci L; Rossi L
    Riv Neurol; 1987; 57(4):245-50. PubMed ID: 3685783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Visual evoked potentials in Alzheimer's and Parkinson disease].
    Zimmer R; Walther H; Kurz A; Haupt M; Lehmann-Horn F; Lauter H
    EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1991 Dec; 22(4):239-45. PubMed ID: 1786786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatosensory, motor and special visual evoked potentials to single and double stimulation in "Parkinson's disease" an early diagnostic test?
    Jörg J; Gerhard H
    J Neural Transm Suppl; 1987; 25():81-8. PubMed ID: 3480940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The electroretinogram and visual evoked potentials in patients with Parkinson's disease].
    Burguera JA; Vilela C; Traba A; Ameave Y; Vallet M
    Arch Neurobiol (Madr); 1990; 53(1):1-7. PubMed ID: 2393335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep brain stimulation of the subthalamic nucleus affects resting EEG and visual evoked potentials in Parkinson's disease.
    Jech R; Růzicka E; Urgosík D; Serranová T; Volfová M; Nováková O; Roth J; Dusek P; Mecír P
    Clin Neurophysiol; 2006 May; 117(5):1017-28. PubMed ID: 16516544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.
    Muthane UB; Satishchandra P; Subhash MN
    Mov Disord; 1993 Jul; 8(3):344-8. PubMed ID: 7688076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ethanol on human visual evoked potentials.
    Resende LA; Adoni T; Kimaid PA; Ragazzo P; Ehlers JA
    Electromyogr Clin Neurophysiol; 2001 Sep; 41(6):349-52. PubMed ID: 11680859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evoked potentials (VEPs and BAEPs) in a large cohort of short- and long-term haemodialysed patients.
    Pagani C; Bazzi C; Arrigo G; Venturini CT; D'Amico G
    Nephrol Dial Transplant; 1993; 8(10):1124-8. PubMed ID: 8272227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of L-dopa on visual evoked potential in patients with Parkinson's disease.
    Bhaskar PA; Vanchilingam S; Bhaskar EA; Devaprabhu A; Ganesan RA
    Neurology; 1986 Aug; 36(8):1119-21. PubMed ID: 3736880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.